Company intelligence / Profile preview

Ananda Development

London, England, United Kingdom

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Ananda Pharma is conducting two Phase 2 randomised controlled trials for their patent-pending MRX1 cannabinoid formulation targeting complex, chronic inflammatory pain in endometriosis and CIPN; additionally, preclinical studies for HFpEF have completed first phase with positive data for cardioprotection[1][5].

Therapeutic areas: CardiovascularWomen's HealthNeurology
Modalities: Small moleculePlant-derived extract
Industry: Biotech

Partnerships

NHS clinical trial collaborations (UK)

Beyond the preview

Go deeper on Ananda Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ananda Development.

Explore the full profile